Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Healthtrust
Merck
Julphar
Chubb
Deloitte
McKesson
Citi
Accenture
Fuji

Generated: October 19, 2017

DrugPatentWatch Database Preview

Forest Labs Inc Company Profile

« Back to Dashboard

What is the competitive landscape for FOREST LABS INC, and what generic alternatives to FOREST LABS INC drugs are available?

FOREST LABS INC has ten approved drugs.

There are ten US patents protecting FOREST LABS INC drugs on FOREST LABS INC drugs in the past three years.

There are eighty patent family members on FOREST LABS INC drugs in thirty-three countries.

Summary for Applicant: Forest Labs Inc

International Patents:80
US Patents:10
Tradenames:10
Ingredients:6
NDAs:10
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Forest Labs Inc
ZENPEP
pancrelipase (amylase;lipase;protease)
CAPSULE, DELAYED RELEASE;ORAL022210-003Aug 27, 2009RXYesNo► Subscribe► Subscribe ► Subscribe
Forest Labs Inc
ZENPEP
pancrelipase (amylase;lipase;protease)
CAPSULE, DELAYED RELEASE;ORAL022210-001Aug 27, 2009RXYesNo► Subscribe► SubscribeY ► Subscribe
Forest Labs Inc
ZENPEP
pancrelipase (amylase;lipase;protease)
CAPSULE, DELAYED RELEASE;ORAL022210-002Aug 27, 2009RXYesNo► Subscribe► SubscribeY ► Subscribe
Forest Labs Inc
ZENPEP
pancrelipase (amylase;lipase;protease)
CAPSULE, DELAYED RELEASE;ORAL022210-003Aug 27, 2009RXYesNo► Subscribe► Subscribe ► Subscribe
Forest Labs Inc
ZENPEP
pancrelipase (amylase;lipase;protease)
CAPSULE, DELAYED RELEASE;ORAL022210-007Mar 25, 2014RXYesNo► Subscribe► SubscribeY ► Subscribe
Forest Labs Inc
ULTRESA
pancrelipase (amylase;lipase;protease)
CAPSULE, DELAYED RELEASE;ORAL022222-003Mar 1, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Forest Labs Inc
ZENPEP
pancrelipase (amylase;lipase;protease)
CAPSULE, DELAYED RELEASE;ORAL022210-005Jun 15, 2011RXYesNo► Subscribe► SubscribeY ► Subscribe
Forest Labs Inc
ZENPEP
pancrelipase (amylase;lipase;protease)
CAPSULE, DELAYED RELEASE;ORAL022210-004Aug 27, 2009RXYesNo► Subscribe► SubscribeY ► Subscribe
Forest Labs Inc
URSO FORTE
ursodiol
TABLET;ORAL020675-002Jul 21, 2004ABRXYesYes► Subscribe► Subscribe► Subscribe
Forest Labs Inc
FETZIMA
levomilnacipran hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL204168-002Jul 25, 2013RXYesNo► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Forest Labs Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Forest Labs Inc
CARAFATE
sucralfate
TABLET;ORAL018333-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Forest Labs Inc
URSO 250
ursodiol
TABLET;ORAL020675-001Dec 10, 1997► Subscribe► Subscribe
Forest Labs Inc
URSO FORTE
ursodiol
TABLET;ORAL020675-002Jul 21, 2004► Subscribe► Subscribe
Forest Labs Inc
RECTIV
nitroglycerin
OINTMENT;INTRA-ANAL021359-001Jun 21, 2011► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for FOREST LABS INC drugs

Drugname Dosage Strength Tradename Submissiondate
levomilnacipran
Extended-release Capsules20 mg, 40 mg, 80 mg and 120 mg
FETZIMA 
7/25/2017

Non-Orange Book Patents for Forest Labs Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,293,229Methods of producing stable pancreatic enzyme compositions► Subscribe
9,259,403Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide► Subscribe
7,074,833Use of the (1S,2R) enantiomer of milnacipran for the preparation of a drug► Subscribe
7,005,452Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Forest Labs Inc Drugs

Country Document Number Estimated Expiration
HungaryE026168► Subscribe
Germany602004031893► Subscribe
New Zealand579047► Subscribe
Japan2006517571► Subscribe
Poland378057► Subscribe
Spain2560527► Subscribe
Norway333987► Subscribe
Denmark1601349► Subscribe
Japan6082691► Subscribe
China103933555► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
Healthtrust
Medtronic
Baxter
Chubb
QuintilesIMS
Express Scripts
Moodys
Colorcon
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot